Navigation Links
Schering-Plough Announces Two European Filings
Date:8/26/2009

KENILWORTH, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older. The company also announced today that the EMEA has validated the MAA for nomegestrol acetate (2.5 mg) / 17 beta-estradiol (1.5mg), a combined oral contraceptive (COC) containing a unique combination of a natural estrogen identical to the estrogen produced by a woman's own body and a selective progestin.

Mometasone furoate/formoterol fumarate combines mometasone furoate, the active ingredient of the inhaled corticosteroid, ASMANEX(R), with formoterol fumarate, the active ingredient of the long-acting beta2-agonist, FORADIL(R), administered via a single metered-dose inhaler.

Marketing approval from the EMEA is being sought for nomegestrol acetate/17 beta-estradiol as an oral treatment for women to prevent pregnancy.

Both applications will follow the Centralized Procedure.

"These two regulatory milestones are important steps toward advancing our late-stage pipeline and meeting patient needs. If approved by the EMEA, the mometasone furoate/formoterol fumarate combination would represent an important additional treatment option for physicians and their patients and further strengthen Schering-Plough's portfolio of respiratory products," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "Schering-Plough is also committed to providing women a variety of birth control options to meet
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Merck/Schering-Ploughs Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Years Analysis of Dyslipidemia
2. PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration
3. Schering-Plough Shareholders Approve Merger With Merck
4. Schering-Plough Reports Financial Results for 2009 Second Quarter
5. Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
6. Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings
7. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
8. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
9. Schering-Plough Schedules Webcast For Annual Meeting of Shareholders
10. Schering-Plough Schedules Conference Call Webcast for 2009 First Quarter Earnings
11. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/18/2013)... Tabletop SEMs are inexpensive and easy to ... performance and capability such as small sample sizes, lower ... provide better imaging performance and more analytical capability but ... higher cost of maintenance. The Pemtron PS-230 and ... types of SEM product, offering competitive prices compared with ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 In support ... sustainability, the Consulate General of Switzerland in New York ... Switzerland’s MS Tûranor PlanetSolar , to Manhattan. ... its DeepWater Expedition 2013 tour with scientists on board ... Capitain Gérard d’Aboville, runs exclusively on energy from the ...
(Date:6/18/2013)... Philadelphia, PA (PRWEB) June 18, 2013 ... fiber-optic Ball Lenses engineered of synthetic Sapphire and Glass ... stock sizes from Swiss Jewel Company , of ... performance by expanding and collimating the light beams without ... extreme optical clarity and natural durability (9 mohs) make ...
Breaking Biology Technology:‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2
... Incorporated (Nasdaq: SPEX ), an innovator in ... and regulatory consulting services to food, supplement, biotechnology and ... the 2009 BIO International Conference in Atlanta, Georgia on ... Control Drug" booth will showcase their ongoing global phase ...
... Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of Action ... May 14 VIA Pharmaceuticals, Inc. (Nasdaq: ... of compounds for the treatment of cardiovascular and metabolic ... a Phase 2 clinical trial of its lead drug, ...
... manufacturing facility opens with substantially increased capacity, ... Biosystems Inc. (TSX:MBX) announced today robust double digit growth ... for the second quarter ended March 31, 2009. , ... of Microbix said "Our 43% growth in the first ...
Cached Biology Technology:Spherix to Exhibit at the BIO 2009 International Convention 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4
(Date:6/18/2013)... of breast and ovarian cancers are familial in origin, ... to inherited mutations from the parents in genes such ... PARP inhibitors, which are currently in clinical trials, have ... for personalised cancer treatment, an alternative to standard chemotherapy. ... these patients generate resistance to the drug and, therefore, ...
(Date:6/18/2013)... of internationally recognized feline experts including veterinarians and feline ... of Lincoln, U.K. and Dr Ilona Rodan, Director of ... International Society of Feline Medicine (ISFM) and the American ... veterinarians, owners and those working with cats on how ... The new guidelines appear in the Journal of ...
(Date:6/17/2013)... high levels of air pollution while pregnant were up to ... women who lived in areas with low pollution, according to ... It is the first large national study to examine links ... findings raise concerns since, depending on the pollutant, 20% to ... where risk of autism was elevated," said lead author Andrea ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... team of Chinese and Swedish researchers rediscovered the breeding area ... the Qinling mountains, Shaanxi province, north central China. Seven ... Changqing National Nature Reserves which almost equals the total ... in the late 19th century. Nearly all of the birds ...
...  Today IBM (NYSE: IBM ) formally unveiled the sixth annual ... innovations that have the potential to change the way people work, ... http://photos.prnewswire.com/prnh/20111219/NY24596 ) (Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO ) ... , You will never need a ...
... Philadelphia, PA -- The Academy of Nutrition and Dietetics ... for Medicare and Medicaid Services (CMS) to expand coverage ... hypertension, obesity, and cancer, as part of the CMS ... conditions can be controlled or treated with medical nutrition ...
Cached Biology News:Sensational bird finding in China 2Sensational bird finding in China 3IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 2IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 3IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 4IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 5IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 6The Academy of Nutrition and Dietetics advocates for expanded nutritional coverage under Medicare 2The Academy of Nutrition and Dietetics advocates for expanded nutritional coverage under Medicare 3
... offers the same benefits as the VSO valve ... is critical or flow is required below 600 ... of gas in proportion to the input current., ... width modulation; closed loop feedback delivers optimal system ...
... from non-demolished blood that is ... The donors are not medicated ... maintained on an antibiotic free ... : 85 mg/ml (by Refractometry).Strain: ...
... Captiva 96-well Filter Plates are offered in ... 0.45 um depth filter plates are ideal ... analysis. Filtration is simple, versatile, and necessary ... The Captiva 10 um glass fiber and ...
... cDNA Labeling System - dUTP with ... For the generation and purification of ... packaged together for complete cDNA labeling ... be used for performing labeling reactions ...
Biology Products: